With long-term use of Platinib, what is the estimated cost of the drug for one year?

Pralsetinib (Pralsetinib) is an oral, highly selective adenosine triphosphate competitive small molecule inhibitor of RET receptor tyrosine kinase. It comes in 100 mg capsules. Platinib is indicated for the treatment of adult patients with RET fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer. Platinib has been approved by regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the National Medical Products Administration and other regulatory jurisdictions.

The recommended dose of platinib in the treatment of non-small cell lung cancer is 400 mg once daily. Treatment should be continued as long as the patient obtains clinical benefit from treatment or until unacceptable toxicity occurs. The cost of one year of long-term use of platinib is expected to vary widely, depending on the source of the drug, dosage, frequency of administration, and the patient's specific circumstances. The specific cost needs to be determined based on the actual situation of the patient and the source of the medicine. Therefore, it is recommended that patients consult a doctor or pharmacist for advice before purchasing drugs to understand various possible drug sources and prices in order to make the most economical and reasonable choice.

In some cases, platinib can be quite expensive. For example, the price of each box of platinib sold in China is about 60,000 yuan, and the monthly dosage is 1 box, so the annual cost reaches about 700,000 yuan. The price of overseas original drugs may be higher. However, if the patient chooses the Laotian imitation platinib, which sells for more than 4,000 yuan per box and uses 1 box per month, the annual cost will be reduced to about 40 million yuan. In addition, there may be market price fluctuations, changes in drug supply and other factors, which will have an impact on drug costs.